NBTX — Nanobiotix S.A.

Nasdaq · Health Care · Pharmaceuticals · CIK 1760854 ·
Last close
$40.80
Market Cap
$1.98B
52W High
$57.14
52W Low
$28.18
ADV30
90,984
Next earnings
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 67,760,000 52,750,000 152,243,000
Jun 2025 45,174,000 28,818,000 114,126,000
Dec 2024 67,418,000 49,737,000 133,121,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-23,961,000
Inventory
Receivables
$7,680,000
ST Investments
EBIT TTM
Pretax Income TTM
Interest Exp TTM
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$32,593,000
EBITDA
$-10,489,000
Free Cash Flow
$-7,894,125
Enterprise Value
$2,026,958,848
Total Cash
$52,750,000
Total Debt
$95,319,000
Shares Out
48,495,512
Trailing EPS
$-0.58
Book Value
$-1.65
ROE
ROA
-10.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 29,643,000 -10,818,000 -23,961,000 67,760,000 152,243,000 -33,422,000
Dec 2024 -11,610,000 -68,392,000 -68,132,000 67,418,000 133,121,000 -19,551,000
Dec 2023 30,058,000 -26,778,000 -39,700,000 93,897,000 95,741,000 -12,476,000
Dec 2022 0 -46,703,000 -57,041,000 59,769,000 86,814,000 -37,103,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$0.15

Peers — same industry

TickerNameMarket CapLastDaily %
TYRA Tyra Biosciences, Inc. $2.00B $33.59
AUPH Aurinia Pharmaceuticals Inc. $1.95B $15.19
BHC Bausch Health Companies Inc. $2.02B $5.40
HCM HUTCHMED (China) Ltd $2.02B $11.75
SION Sionna Therapeutics, Inc. $1.94B $42.88

News headlines (Yahoo Finance, 1h cache)

NANOBIOTIX Announces Closing of Global Offering
2026-05-26 20:59 · Yahoo
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
2026-05-22 20:15 · Yahoo
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
2026-05-21 14:57 · Yahoo
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
2026-05-21 13:30 · Yahoo
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Uncertainty Surrounding US-Iran Talks
2026-05-21 13:18 · Yahoo
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
2026-05-21 06:30 · Yahoo
Nanobiotix Announces Launch of Global Follow-On Offering
2026-05-20 22:19 · Yahoo
How Nanobiotix Got Wall Street's Attention By Using Physics To Battle Cancer
2026-05-20 12:00 · Yahoo
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
2026-05-17 14:15 · Yahoo
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
2026-05-04 21:29 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.